Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.47 |
| ▸ | CCR2 | P41597 | 7/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | BAD | Q92934 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276218 | 0.84 | FDPS (0.56) | FDPSCCR2CMA1MCL1F10 | |
| SCHEMBL3277134 | 0.81 | F10 (0.57) | FDPSCCR2CMA1MCL1F10 | |
| SCHEMBL3283184 | 0.80 | CCR2 (0.60) | FDPSCCR2CMA1MCL1F10 | |
| SCHEMBL3276445 | 0.78 | CCR2 (0.55) | FDPSCCR2CMA1MCL1PIK3C2B | |
| SCHEMBL3275507 | 0.77 | CCR2 (0.62) | FDPSCCR2CMA1MCL1FABP4 | |
| SCHEMBL3283197 | 0.75 | CCR2 (0.56) | FDPSCCR2CMA1MCL1F10 | |
| SCHEMBL3276828 | 0.75 | CCR9 (0.56) | FDPSCCR2CMA1MCL1PIK3C2B | |
| SCHEMBL3280311 | 0.75 | CCR2 (0.55) | FDPSCCR2CMA1MCL1 | |
| SCHEMBL3283142 | 0.73 | CCR2 (0.61) | FDPSCCR2MCL1 | |
| SCHEMBL3276471 | 0.73 | CCR2 (0.76) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | claimed |
| EP-1966134-B1 | NOVEL FUSED PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-1966134-B1 | NOVEL FUSED PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1966134-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068621-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068621-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142452-A1 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142452-A1 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142452-A1 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142452-A1 | Fused pyrrole derivatives | CMA1, PREP, CPA3 | FDPS 1977/4885CCR2 2308/4885CMA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.